The following content should be added to the Cell Culture and Treatment section of the Materials and Methods on page 8276 to explain why a rat cell line (H9c2) was chosen for this study.
“Cardiac dysfunction has been linked with increased morbidity and mortality in sepsis patients. Human primary cardiomyocytes are difficult to obtain. Rat H9C2 cardiomyocytes have been widely used for studying cardiotoxicity, inducing LPS-induced damages in cardiomyocytes.”
The following content should be added to the Western Blot Assay section of the Materials and Methods on page 8276 to explain how nuclear/cytosolic fractions were obtained.
“Nuclear fractions were prepared using a commercial nuclear/cytosol extraction NE-PER kit (Thermo Fisher Scientific, USA). In brief, the cells were trypsinized and collected as a cell pellet. After being washed with PBS, the cells were mixed with ice-cold CER I solution and vortexed to fully suspend the cell pellet. Next, the cell mixture was incubated on ice for 10 min and then reacted with CER II solution. The cytoplasmic protein was collected by centrifugation. The remaining nuclear pellet was treated with NER buffer and centrifuged to remove insoluble debris.”
The following content should be added to the Western Blot Assay section of the Materials and Methods on page 8276 to clarify details of the procedure employed to determine protein concentration.
“Protein concentration was quantified with a BCA kit (Beyotime, Shanghai, China). The bovine albumin standard was diluted as suggested by the manual. First, 25 μL of sample or standard dilute was reacted with BCA working reagent (equal amount of reagent A with reagent B) at 37 °C for 30 min. The absorbance was measured at 562 nm on a microplate reader (Bio-Tek, USA). The concentration of samples was calculated based on the standard curve.”
In Figure 8B, Lamin B1 was used as a control for nuclear proteins in Western blot experiments. This is not mentioned in the Materials and Methods. The following content should be added to the Western Blot Assay section of the Materials and Methods.
“Lamin B1 (Cell Signaling Technology, 1:3000, USA)”.
The following notification should be made to the Discussion section to specify the parameters that constitute “severe inflammation” as induced by LPS in this study.
The sentence “In the present study, the TLR4/Myd88/NF-κB signaling pathway was found to be significantly activated in H9c2 myocardial cells by stimulation with LPS, accompanied by the elevated production of inflammatory factors. By treatment with dulaglutide, the activated TLR4/Myd88/NF-κB signaling pathway and activated inflammation were dramatically alleviated, indicating a pronounced inhibitory effect of dulaglutide against inflammation in myocardial cells induced by LPS” in Page 8275 should be replaced by “The activation of inflammation pathway and secretion of cytokines are critically implicated in inflammatory response in cardiac tissue. In our study, we showed LPS activated TLR4/Myd88 and NF-κB signaling pathways. As a result, LPS induced high production of pro-inflammatory cytokines in H9c2 myocardial cells, such as TNF-α, IL-1β, and IL-17. By treatment with dulaglutide, the activated TLR4/Myd88/NF-κB signaling pathway and the increased TNF-α, IL-1β, and IL-17 were dramatically alleviated, indicating that the severe inflammation induced by LPS was greatly alleviated by treatment with dulaglutide.”
The above corrections do not change any of the conclusions of the paper. We apologize for any inconvenience.